XPC protects against smoking- and carcinogen-induced lung adenocarcinoma by Zhou, Huaxin et al.
Carcinogenesis, 2019, Vol. 40, No. 3, 403–411
doi:10.1093/carcin/bgz003
Advance Access publication April 10, 2019
Original Manuscript
403
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Received: June 5, 2018; Revised: December 21, 2018; Accepted: January 4, 2019
Original Manuscript
XPC protects against smoking- and carcinogen-induced 
lung adenocarcinoma
Huaxin Zhou1, Jacob Saliba1, George E.Sandusky2 and Catherine R.Sears1,3,* 
1Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Department of Medicine, and  2Department of 
Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA and 3The Richard 
L. Roudebush Veterans Affairs Medical Center, Indianapolis, IN 46202, USA
*To whom correspondence should be addressed. Tel: +1 317 278 0413; Fax: +1 317 278 7030; Email: crufatto@iu.edu
Abstract
Cigarette smoke (CS) contains hundreds of carcinogens and is a potent inducer of oxidative and bulky DNA damage, 
which when insufficiently repaired leads to activation of DNA damage response and possibly mutations. The DNA repair 
protein xeroderma pigmentosum group C (XPC) is primed to play an important role in CS-induced DNA damage because 
of its function in initiating repair of both bulky oxidative DNA damage. We hypothesized that loss of XPC function will 
increase susceptibility to developing CS- and carcinogen-induced lung cancer through impaired repair of oxidative DNA 
damage. Mice deficient in XPC (XPC−/−) exposed to chronic CS developed lung tumors whereas their wild-type littermates 
(XPC+/+) did not. XPC−/− mice treated with the CS-carcinogen urethane developed lung adenocarcinomas representing 
progressive stages of tumor development, with lung tumor number increased 17-fold compared with XPC+/+ mice. Mice 
heterozygous for XPC (XPC+/−) demonstrated a gene–dose effect, developing an intermediate number of lung tumors with 
urethane treatment. Treatment of XPC−/− mice with the carcinogen 3-methylcholanthrene followed by the proliferative 
agent butylated hydroxytoluene resulted in a 2-fold increase in lung adenocarcinoma development. Finally, tumor number 
decreased 7-fold in the lungs of XPC−/− mice by concurrent treatment with the antioxidant, N-acetylcysteine. Altogether, 
this supports a mechanism by which decreased XPC expression promotes lung adenocarcinoma development in response 
to CS-carcinogen exposure, due in part to impaired oxidative DNA damage repair.
Introduction
Lung cancer is the leading cause of cancer deaths in the USA and 
Western European countries, and the number of lung cancers is 
increasing worldwide (1,2). Cigarette smoke (CS) is the primary 
exposure leading to the development of lung cancer, of which 
85% are classified as non-small cell lung cancers (NSCLCs), with 
most prevalent histologic type being adenocarcinoma (3). The 
effects of CS on cell metabolism and function are many, but 
the primary carcinogenic CS effect is DNA damage. CS contains 
hundreds of carcinogens and direct exposure in the lung leads to 
a variety of DNA lesions, including bulky DNA adducts [such as 
polycyclic aromatic hydrocarbons (PAHs)] formed directly from 
carcinogens, oxidized DNA bases caused by CS-induced increases 
in oxidative stress, and single-strand and double-strand breaks 
caused by oxidative stress and/or repair intermediates (4,5). 
Although the connection between CS and lung cancer has been 
well established, less well understood is the mechanism by 
which CS-induced DNA lesions and DNA damage repair lead 
to lung cancer. Only 10–15% of smokers develop lung cancer, 
and it has been postulated that other exposures, epigenetic 
changes and/or genetic predisposition may be necessary in 
addition to CS exposure for lung cancer development (6). For 
instance, cigarette smokers with emphysema are at increased 
risk for lung cancer development compared with those without 
emphysema. This suggests that there may be a predisposing 
factor by which patients develop the seemingly disparate lung 
findings in emphysema (characterized by progressive loss of 
alveolar cells and structure) and lung cancer (characterized by 
unchecked cellular proliferation).
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Altered DNA repair capacity is considered a hallmark 
of cancer, leading to mutations and genomic instability 
(7). Decreased DNA repair capacity could be due to genetic 
predetermination or acquired in precancerous or cancerous 
lesions. In humans, decreased DNA repair capacity has been 
described as a risk factor for NSCLC development, and higher 
levels of DNA damage are observed in lung cancers (8), further 
supporting an important role for impaired DNA repair playing a 
critical role in lung cancer development.
The DNA repair protein, xeroderma pigmentosum group C 
(XPC), has a canonical role in the repair of bulky DNA damage, 
such as polycyclic aromatic hydrocarbons (PAHs), through 
global genomic nucleotide excision repair (GG-NER). Together 
with Rad23A/B and Centrin2, XPC initiates GG-NER through 
identification of DNA strand distortion from large, bulky DNA 
lesions throughout both transcribed and non-transcribed regions 
of the genome (9). An overlapping repair process, transcription-
coupled NER, occurs when RNA polymerase II is stalled at bulky 
DNA lesions within actively transcribed regions of the genome. 
Downstream of the initial DNA damage recognition, these two 
NER pathways are identical (10). More recently, XPC has been 
implicated in repair of oxidative DNA lesions including 8-OHdG. 
Although the exact mechanism is yet to be fully elucidated, 
XPC recognition of the oxidative DNA lesion, 8-OHdG has been 
described in vitro and augmentation of base excision repair (BER) 
glycosylase activity of human 8-oxoguanine DNA glycosylase 
(hOgg1), and XPC augmentation of other BER proteins, Single-
Strand-Selective Monofunctional Uracil-DNA Glycosylase 
11 and thymidine-DNA glycosylase, have been described in 
vitro (11–14). In addition, increased oxidative DNA damage is 
observed in mice deficient in XPC when exposed to prooxidants 
in vivo (15). Given close associations between lung CS exposure, 
increased oxidative stress and associated DNA damage, this 
raises and intriguing possibility that XPC may be involved in 
repair of CS-induced DNA lesions through its role in GG-NER, 
BER of oxidative DNA damage or both.
A link between XPC deficiency and cancer development 
has been well established, as humans deficient in XPC develop 
melanomatous and non-melanomatous skin cancers early in 
life and at an increased number and severity when exposed to 
ultraviolet light. With these patients living longer by limiting 
sun exposure, XPC patients develop solid organ tumors at an 
increased incidence compared with the general population 
(16). In addition, epidemiologic studies suggest an association 
between common XPC polymorphisms and an increase in solid 
organ tumors, including lung cancers, although there is some 
debate regarding a link to CS exposure (17). Two XPC knockout 
mouse models exist, both of which develop characteristic skin 
cancers with exposure to ultraviolet light (13). XPC-deficient mice 
develop de novo precancerous and early cancerous lung tumors 
with advancing age (18). When exposed to oxidizing conditions, 
these mice were observed to show an increase in oxidative DNA 
damage and mutations in the liver compared with wild-type 
(WT) XPC mice (15). Mice deficient in xeroderma pigmentosum 
group A (XPA), which is essential for GG-NER and transcription-
coupled NER, did not develop an increase in lung tumors with 
age compared with controls, suggesting that XPC may play a 
unique role in lung cancer development (19). More recently, we 
showed that XPC alters the DNA damage response to CS in lung 
epithelial cells in vitro, protecting cells from CS-induced extrinsic 
apoptosis and cell death, and protects against CS-induced 
emphysema in mouse models of CS exposure (20). However, it is 
not known how XPC affects development of CS- and carcinogen-
induced lung cancer development.
Here we directly investigate the role of XPC in CS-induced lung 
cancers. We hypothesized that XPC deficiency would accelerate 
lung cancer development in mice exposed to chronic CS. Using a 
long-term CS exposure mode, we show that XPC-deficient mice 
are predisposed to development of precancerous and cancerous 
lung tumors compared with their WT littermates. Using two 
potent carcinogen models, we show that XPC knockout (XPC−/−) 
mice develop lung cancers of adenocarcinoma histologic type 
at an increased number compared with XPC WT (XPC+/+) 
littermates, with those mice heterozygous for XPC showing an 
intermediate number of tumors. Treatment with the antioxidant 
N-acetylcysteine (NAC) decreased urethane-induced tumor 
development, further supporting a role for XPC in repair of 
oxidative DNA damage. Altogether, this supports an important 
role of XPC in protecting against CS-induced lung cancer 
development.
Materials and methods
Chemicals
Urethane (ethyl carbamate), NAC, 3-methylcholanthrene (MCA) and 
butylated hydroxytoluene (BHT) were purchased from Sigma (St. Louis, 
MO). Other compounds and reagents purchased from Thermo Fisher 
Scientific (Waltham, MA), unless otherwise noted.
Animals
All mice experiments were conducted according to a Laboratory Animal 
Resource Center (LARC)-approved lab animal protocol. Mice heterozygous 
for XPC (mixed C57BL/6; 129 background) were purchased from Jackson 
Laboratories (Bar Harbor, ME), bred and genotyped as published previously 
(20). These mice had been back-crossed more than 10 generations prior to 
use. Littermate male and female mice, aged 6–8 weeks of age, were used 
for these experiments and maintained in accordance with institutional 
guidelines and approved by our local institutional animal care and use 
committee (IACUC) as published (20).
Mouse CS and carcinogen exposure models
For chronic CS exposure models, mice were exposed to reference 
cigarettes (3R4F; Tobacco Research Institute) for 5 h/day, 5 day/week via 
a TE-10 smoking device or ambient air (air control, AC) for the indicated 
durations as described previously (20). Chronic CS exposures were either 
9  months continuous CS (or AC) or 5  months CS followed by 4  months 
AC (or 9 months AC) in XPC+/+ and XPC−/− mice, followed by necropsy. 
Experiments were performed in duplicate, total 18–20 mice per group. 
Mice (XPC+/+, XPC+/− and XPC−/−) received intraperitoneal (i.p.) injections 
of urethane at a dose of 1 g/kg body wt in phosphate-buffered saline (PBS) 
or vehicle (PBS) control weekly for 6 weeks and necropsy performed 26 
Abbreviations  
AC air control
BAL bronchoalveolar lavage
BER base excision repair
BHT butylated hydroxytoluene
CS cigarette smoke
CSE CS extract
GG-NER global genomic nucleotide excision 
repair
i.p. intraperitoneal
MCA 3-methylcholanthrene
NAC N-acetylcysteine
NSCLC non-small cell lung cancer
PAH polycyclic aromatic hydrocarbon
PBS phosphate-buffered saline
WT wild-type
XPC xeroderma pigmentosum group C
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weeks after initial urethane injection (21). Urethane mouse exposure 
experiments were performed in duplicate or triplicate for each treatment 
condition with animal numbers per group as detailed in Table 1. The MCA-
BHT model was performed by i.p. injection of MCA in Mazola oil (15 mg/kg 
body wt) on week 1, followed by i.p. injection of BHT in Mazola oil (150 mg/
kg body wt) on week 2 and subsequent i.p. injections of BHT in Mazola oil 
(200 mg/kg body wt) weekly on weeks 3–7, with necropsy performed 26 
weeks after initial urethane injection (22). Experiments were performed in 
duplicate in XPC+/+ and XPC−/− mice, total of 12–16 per group. NAC was 
provided ad libitum in drinking water (~40 mM in water buffered to pH 7.4), 
changed three times a week (23). Lung harvest and bronchoalveolar lavage 
(BAL) were performed as described previously (20).
Tissue specimen collection and processing
All mice tissue samples were collected following a detailed LARC-approved 
lab animal protocol. In the histology study, lungs were fixed in 10% neutral 
buffered formalin at 4°C for 48  h following tissue processing and then 
embedded in paraffin. Four-micrometer sections were stained for routine 
hematoxylin and eosin staining or unstained for immunostaining.
Isolation and culture of Type 2 pneumocytes
Isolation of type 2 pneumocytes from mouse lungs was performed as 
previously described (24) with minor alterations. Briefly, mice were 
exsanguinated and perfused with sterile 0.9% saline solution. The trachea 
was cannulated, dispase (1  mg/ml in PBS, Worthington Biochemical) 
instilled followed by 1% low melting point agarose and solidification on 
ice for 2 min. Lungs were then removed and incubated in 2 ml dispase 
solution for 45  min with agitation (25°C). Lung tissue was teased apart 
from bronchi in a sterile petri dish containing 7 ml Dulbecco’s modified 
Eagle’s medium + 0.01% DNase I  (Sigma). The cell suspension was 
incubated with red blood cell lysis buffer and filtered through sequentially 
smaller filters (70 μm, 40 μm) and nylon mesh (25 μm). Cells were labeled 
with biotinylated anti-CD45 and anti-CD16/32 antibodies, followed by 
incubation with magnetic streptavidin microbeads and negative selection 
through a magnetic-activated cell sorting microcolumn per manufacturer 
protocol (Miltenyi Biotec). These cells were plated on non-coated, tissue 
culture plates for 8 h, and the non-adherent cells collected and plated on 
fibronectin coated plates for additional experiments. Confirmation of type 
2 pneumocytes by immunofluorescence microscopy staining using rabbit 
anti-mouse pro-SPC (AB3786, Millipore, 1:200) (25).
Comet assay
Assessment of DNA damage was performed by alkaline comet assay as 
published previously (26). Briefly, CS extract (CSE, 100%) was prepared by 
bubbling ambient air (AC) or smoke from two 3R4F cigarettes (CSE) into 
20 ml PBS, adjusting the pH to 7.4, and passing through a 0.2 μm filter (20). 
Following 12 h of serum starvation, cells were cultured with AC or 5% CSE 
for 24 h. Cells are suspended in low-melting-point agarose and spread on 
prepared coverslips. Once solidified, the cells are lyzed and DNA unwound 
using an alkaline solution (2.5 M NaCl, 100 mM ethylenediaminetetraacetic 
acid, 10 mM Tris, 1% Triton X-100, pH 10) and single-cell electrophoresis 
performed according to manufacturer instructions (Trevigen). Slides were 
dehydrated in alcohol and stained with SYBR gold. Images were obtained 
at ×10 magnification (fluorescein isothiocyanate filter) using a Nikon 
Eclipse 90i microscope, captured by digital camera using NIS Elements. 
Analysis of ≥50 comets was determined using CometScore (TriTek). Mean 
tail DNA percentage from each of three independent experiments was 
compared using analysis of variance.
Immunostaining
The slides were deparaffinized in xylene and rehydrated using graded 
alcohols and water. Antigen retrieval was performed by immersing the 
slides by boiling in sodium citrate (pH 6.0) and endogenous peroxidase 
quenched with 3% hydrogen peroxide. Slides were blocked with in 
PBS-Tween 0.05% (Vector ABC Kit). Primary antibodies were diluted in 
Dako antibody diluent and biotinylated universal antibodies (Vector). 
Staining was performed using avidin–biotin complex horseradish 
peroxidase (ABC reagent, Vector) followed by diaminibenzidine substrate 
(Vector). A thorough washing was performed following each incubation. 
Counterstaining was performed using hematoxylin where indicated. The 
primary antibodies used for include the following: TTF1 (Abcam), 8-OHdG 
(N45.1, Abcam) and was performed as published previously (20).
Statistical analysis
Unless otherwise noted, statistical analysis was by analysis of variance 
using SigmaPlot (Systat Software) with statistical significance defined as 
P < 0.05.
Results
Deficiency in XPC promotes CS-induced lung 
adenocarcinoma
To evaluate the impact of XPC on smoking-induced lung 
cancer development, we exposed WT (XPC+/+) and XPC-
deficient littermates (XPC−/−) aged 6–8 weeks, to chronic 
CS using a TE-10 smoking device (Figure 1A). Exposing these 
mice to 9  months chronic CS, we observed an increase in 
precancerous changes within the pulmonary epithelial cells 
in both XPC−/− and +/+ mice. The precancerous changes were 
more pronounced in XPC−/− mice, consisting of hyperplasia, 
atypia and dysplastic cells (Figure 1B). None of these mice 
developed frank lung tumors on both gross and microscopic 
examination. This was not surprising; although chronic 
CS exposure leads to lung cancer development in humans, 
Table 1. Mouse tumor development and deaths according to genotype and treatment type.
Genotype Treatment Deaths
Mice with lung tumors (at time of planned 
necropsy) Other findings
XPC+/+ PBS (control) 2/19a
 Females: 2/10
0/14
XPC+/+ Urethane 3/22a
 Female: 0/11
12/19 Lymphoma
XPC+/− PBS (control) 0/7 0/7  
XPC+/− Urethane 1/19
 Female: 1/10
17/18b Ovarian mass (adenoma, 
TTF1 neg)
XPC−/− PBS (control) 0/13 0/13  
XPC−/− Urethane 1/35
 Female: 0/19
34/34b Lymphoma and thymic mass
XPC−/− Urethane + NAC 5/18
 Female: 5/11
12/13 Lymphoma
aOne XPC+/+ PBS (control) and two XPC+/+ urethane-treated mice deaths because of complications of i.p. injection.
bMice that died prior to harvest found to have multiple lung tumors.
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mouse models of CS exposure uniformly require chronic 
exposure to CS for several months followed by months of 
withdrawal from the exposure (27). In order to better align our 
cigarette smoking model to published models of lung cancer 
development in mice (28), we then exposed XPC+/+ and −/− 
mice to 5  months CS followed by 4  months of AC (Figure 
1A). No tumors were observed on the lung surface by gross 
examination. On microscopic evaluation, both precancerous 
lesions and malignant tumors were observed only in XPC−/− 
mice. Precancerous changes included bronchiolar epithelial 
hyperplasia (Figure 1C), some with focal dysplastic features 
(Figure 1D). Other tumors showed histology characteristic 
of early bronchoalveolar carcinoma (Figure 1E) with some 
advancing to histologic characteristics similar to that 
observed in human adenocarcinoma in situ (Figure 1F and G).
Lung bronchoalveolar carcinomas typically arise from 
type 2 pneumocytes, found within the alveolar region of the 
lung. To further link impaired DNA repair to the increase in 
precancerous and malignant tumors observed in our smoking 
model, we evaluated the impact of XPC on DNA damage using 
type 2 pneumocytes from the lungs of XPC+/+ and −/− mice. 
High purity of type 2 pneumocyte isolation was confirmed by 
immunofluorescence microscopy for the type 2 pneumocyte-
specific proteins, pro-SPC (Figures 2A and B). In primary murine 
type II alveolar cells, XPC expression protected against CSE-
induced DNA damage as measured by alkaline comet assay 
(P  <  0.001, Figure 2C). This further supports a role for XPC in 
protection against CS-induced DNA damage.
XPC deficiency increases urethane-induced lung 
adenocarcinoma
The murine CS-lung cancer model is a low-potency model for this 
strain of mouse (28). Given a signal of increased precancerous 
and malignant lung cancer development in XPC−/− mice in 
chronic CS, we further investigated the impact of XPC using a 
more robust urethane lung cancer carcinogen model.
Urethane is one of more than 7000 potentially carcinogenic 
compounds found in CS (4). On the basis of previous exposure 
models for C57BL/6 mice (21), littermate XPC+/+ and −/− mice 
aged 6–8 weeks were exposed to weekly urethane weekly for a 
total of 6 weeks and then evaluated for tumor development at 
26 weeks (Figure 3A). Urethane exposure led to the development 
of grossly visible lung cancers in both XPC+/+ and −/− mice 
(Figure 3B). By visual inspection of the lung surface at the 
time of necropsy, XPC−/− mice averaged 17 times the number 
tumors compared with XPC+/+ (P < 0.001, Figure 3B and C). The 
tumors observed in the urethane-treated XPC−/− mice showed 
a range of histologic appearance and progression similar to 
the development of human adenocarcinoma by hematoxylin 
and eosin stain, ranging in histologic appearance from atypical 
adenomatous hyperplasia to adenoma to adenocarcinoma in 
situ and finally minimally invasive adenocarcinoma (Figure 3D, 
subpanels a–d). Adenocarcinoma histologic subtype was further 
supported by tumor positive TTF1 immunohistochemical 
analysis (Figure 3E). Treatment with urethane resulted in an 
increase in total BAL cell count, characterized as predominantly 
lymphocytes, in treated XPC−/− mice (Supplementary Figure 1A 
Figure 1. Morphology of CS exposed XPC-deficient and wild-type mice lungs. (A) Schematic of CS and AC exposed mice for the following morphologic evaluations. 
(B) Representative images of hematoxylin and eosin (H&E) stained lung epithelial cells showing precancerous changes including hyperplasia and atypia in an XPC-
deficient (−/−) mouse exposed to 9 months of CS. XPC−/− mice exposed to 5 months CS followed by 4 months AC showed bronchiolar epithelial hyperplasia (C, D) with 
dysplasia (D), early bronchioloalveolar adenoma (E) with adenocarcinoma in situ (F). Immunohistochemical analysis (IHC) confirmed TTF1+ staining, consistent with 
adenocarcinoma-type histology (G). ×200 magnification. Wks, weeks; Mos., months.
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and B, available at Carcinogenesis Online). Tumor number and size 
were not influenced by male or female sex, and tumor size was 
not affected by XPC expression (Supplementary Figure 1C and 
D, available at Carcinogenesis Online). Mice heterozygous for XPC 
(XPC+/−) developed an intermediate number of lung tumors with 
urethane exposure, averaging greater than twice the number 
of tumors compared with their XPC+/+ littermates (Figure 3F). 
These findings are highly suggestive of a protective effect of XPC 
against carcinogen exposure which may be dose-dependent.
XPC protects against urethane-induced lung cancers, 
in part through repair of oxidative DNA damage
We and others have suggested a role for XPC in repair of 
oxidative DNA lesions through the repair of oxidized DNA 
lesions through the BER pathway (11,15,20). The carcinogenic 
effects of urethane are believed to be related to the development 
of etheno adducts and oxidative lesions on DNA, both of which 
are repaired by the BER pathway (29,30). Lung tumors from 
XPC+/+ and −/− mice were stained for the oxidative DNA lesion, 
8-OHdG. Strong immunohistochemical staining for 8-OHdG was 
observed in all lung tumors in both XPC+/+ and −/− mice (Figure 
4A). To further investigate whether XPC protects against lung 
cancer development through repair of oxidative DNA damage, 
we provided mice with the antioxidant chemical, NAC (40 mM), 
in drinking water for 26 weeks (Figure 3A). Treatment with NAC 
resulted in a greater than 3-fold reduction in tumor number in 
XPC−/− mice compared with those treated with urethane alone 
(P < 0.001, Figure 4B) with no observed difference in tumor size 
(Supplementary Figure 2A, available at Carcinogenesis Online). 
The reduction in tumor number in XPC−/− mice treated with 
urethane + NAC was observed in both male and female mice 
(Supplementary Figure 2B, available at Carcinogenesis Online). 
However, death prior to scheduled necropsy was observed 
only in female XPC−/− mice receiving NAC (5/11 XPC−/− female 
mice receiving urethane + NAC compared with 0/12 XPC−/− 
mice receiving urethane alone) (Table 1). Interestingly, in those 
mice that survived to 26 weeks, no significant difference was 
observed in BAL cell count or differential in those mice receiving 
NAC in addition to urethane compared with those receiving 
urethane alone (Supplementary Figure 2C and D, available at 
Carcinogenesis Online).
To further define the mechanism by which XPC protects 
against CS-induced lung cancer development, we used another 
well-established murine model of lung adenocarcinoma 
development by exposing mice to the carcinogen MCA followed 
by BHT. XPC+/+ and −/− mice aged 6–8 weeks were exposed to 
one i.p. injection of MCA followed by 6 weekly i.p. injections 
of BHT (Figure 5A). At 24 weeks, there was a significant but 
modest increase in the number of tumors visible on the 
lung surface in XPC−/− mice when compared with +/+ mice, 
with XPC−/− mice treated with MCA-BHT developing twice 
the number of lung tumors as MCA-BHT-treated XPC+/+ 
mice (Figure 5B). Early malignant changes, corresponding in 
appearance to atypical adenomatous hyperplasia in humans, 
were observed in XPC+/+ mice treated with MCA-BHT. In 
XPC−/− mice treated with MCA-BHT, the tumors showed 
bronchoalveolar adenoma-type histology similar to human 
adenocarcinoma (Figure 5C and D), further confirmed by 
TTF-1 positive staining by immunohistochemical analysis 
(Figure 5E). As expected, an increase in BAL cell count and 
macrophages was observed in all mice treated with MCA-BHT 
but was independent of XPC genotype (Supplementary Figure 
3, available at Carcinogenesis Online). These findings suggest 
that XPC repair of both oxidative and bulky (NER-repaired) 
DNA damage is probably involved in carcinogen-induced lung 
cancer development.
Discussion
In this study, we show that XPC plays an important role in 
CS carcinogen-induced lung cancer development. Using a 
murine model of CS exposure, we show that XPC deficiency 
accelerates precancerous changes and leads to development 
of a spectrum of murine lung bronchioloalveolar carcinomas 
with characteristics similar to human lung adenocarcinomas, 
ranging in histologic appearance from atypical adenomatous 
hyperplasia to adenoma to adenocarcinoma in situ and finally 
minimally invasive adenocarcinoma. A  critical role of XPC in 
Figure 2. Impact of XPC on CS-induced DNA damage in type 2 pneumocytes. (A) Representative immunofluorescence microscopy image of pro-SPC staining in isolated 
type 2 pneumocytes compared with cells isolated from unselected lung cells (whole lung). Pro-SPC staining is shown in green, 4′,6-diamidino-2-phenylindole (DAPI) 
(nuclear) staining is shown in blue. ×200 magnification. (B) Mean percent type 2 pneumocytes (% pro-SPC) from the lungs of mice (n = 3) used in the subsequent experi-
ment+/− standard error of the mean (SEM). Percent type 2 pneumocytes in whole lung isolate from XPC+/+ mice (shown for comparison) did not differ from that 
observed in whole lung isolate from XPC−/− mice (data not shown). **P < 0.01 compared with whole lung. (C) Quantification of percentage of DNA in tail by alkaline 
comet assay in primary type II pneumocytes (XPC+/+ and XPC−/−) treated with AC or 5% CS extract CSE for 24 hours. Dots indicate the means of three independent 
experiments, each with ≥ 50 comets scored. Hydrogen peroxide (H2O2) shown as a positive (high DNA damage) control. ***P < 0.001.
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CS carcinogen-related lung cancers is further supported by 
increased number of lung adenocarcinomas in XPC-deficient 
mice treated with two carcinogen models: urethane and MCA-
BHT. These mouse models support a mechanism by which XPC 
deficiency leads to persistent DNA damage in XPC-deficient 
lung cells.
Carcinogen-induced DNA damage is believed to be the major 
driver of lung cancer development in smokers, with impaired 
DNA repair leading to mutations and ultimately cancer. 
However, how this occurs remains little understood. XPC has 
been implicated in lung cancer development. Several studies 
have proposed a link between common polymorphisms of XPC 
Figure 3. Impact of XPC on urethane-induced lung cancers. (A) Schematic of urethane experiments performed using XPC wild-type and deficient mice. (B) Representative 
gross images of lungs from XPC wild-type (+/+) and deficient (−/−) mice treated with urethane. Black arrow heads represent tumors visible on the lung surface. (C) 
Quantification of visible lung tumors in XPC+/+ and −/− mice treated with urethane. (D) Representative hematoxylin and eosin (H&E) of lungs from XPC-deficient mice 
showing progression of tumor from atypical adenomatous hyperplasia (a) to adenoma (b) to adenocarcinoma in situ (c) and minimally invasive adenocarcinoma (d) 
often within the same mouse. (E) Immunohistochemical analysis (IHC) confirmed TTF1+ staining, consistent with adenocarcinoma-type histology. (F) Quantification of 
visible lung tumors in XPC+/+, XPC heterozygous (+/−) and XPC−/− mice treated with urethane. *P < 0.05, **P < 0.01, ***P < 0.001.
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and lung cancer development, although results have varied 
(31–34). XPC-deficient mice develop precancerous changes 
and adenomas with advanced age, and previous studies have 
suggested an important role for oxidative stress and oxidative 
DNA damage in cancer development (15). In Figure 1, we show 
a direct link between decreased XPC expression and CS- and 
carcinogen-induced lung cancer development in mice. XPC−/− 
mice showed acceleration of precancerous changes when 
exposed to chronic CS for 9 months and required withdrawal of 
CS (5 months of CS followed by 4 months of AC) for lung cancers 
to develop. This is not surprising, given that multiple studies 
support the requirements of an AC recovery period after CS for 
a murine model of lung cancer development (27). Of interest 
is that none of the XPC+/+ mice develop lung cancers after 
5 months CS followed by 4 months of AC. We suspect this is due 
to a combination of the protective effects of XPC combined with 
a very low susceptibility of both the C57BL/6 and 129 mouse 
strains to induction of lung cancers by this method of chronic 
CS exposure, as has been observed previously (28).
Given the relatively low potency of the CS-lung cancer model 
in these mice, we turned to carcinogen lung adenocarcinoma 
models to evaluate the mechanism by which XPC protects 
against lung cancer development. As expected, we observed and 
increase in lung adenocarcinoma development in urethane-
treated mice deficient in XPC when compared with their WT 
littermates (Figure 3). XPC+/− mice develop an intermediate 
number of lung tumors when treated with urethane compared 
with XPC−/− and XPC WT mice (Figure 4B), further supporting a 
mechanism by which the level of XPC expression contributes to 
development of CS carcinogen lung adenocarcinomas. Although 
XPC deficiency is rare, common polymorphisms or deletions 
of chromosome 3p, as commonly found in lung cancers 
(18,32,33,35), may result in intermediate levels of expression 
and/or function. Low XPC messenger RNA expression has also 
been associated with a shorter recurrence-free survival in 302 
patients with resected NSCLC (36). Our finding that XPC+/− 
mice develop an intermediate number of lung tumors when 
treated with urethane suggests that loss of heterozygosity or 
Figure 4. Impact of antioxidant treatment on urethane-induced lung cancer development in XPC-deficient mice (A) Immunohistochemical stain showing staining 
for 8-oxo-2′-deoxyguanosine (8-OHdG) in lower grade (adenoma, left) and higher grade (adenocarcinoma, right) tumors in the lung. (B) Quantification of lung tumors 
visible on the surface of mouse lungs in XPC-deficient (−/−) mice administered either drinking water or drinking water supplemented with NAC in addition to urethane. 
***P < 0.001
Figure 5. Impact of XPC on MCA-BHT-induced lung cancers. (A) Schematic of 3-methylcholanthrene-butylated hydroxytoluene (MCA-BHT) experiments performed 
using XPC wild-type and deficient mice. (B) Quantification of visible lung tumors in XPC+/+ and XPC−/− mice treated with MCA-BHT. (C and D) Representative 
hematoxylin and eosin stained sections of lung from XPC-deficient mice showing lung tumors of advancing adenocarcinoma histology. (E) Immunohistochemical 
analysis (IHC) confirmed TTF1+ staining, consistent with adenocarcinoma-type histology. *P < 0.05
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single XPC mutations, either through early malignant genomic 
changes or through genetic predisposition, may be sufficient 
for tumor development. The dose of urethane used in these 
studies is standard for development of adenocarcinoma in this 
mouse strain (21), however, one should use caution in directly 
correlating these results to CS-induced lung cancer, as the dose 
of urethane to which mice were exposed are much higher than 
that found in CS, and additional chemicals found in CS may 
impact of XPC on lung adenocarcinoma development as well.
This study shows a strong link between decreased DNA 
repair by XPC and lung cancer development in CS and 
carcinogen-exposed lung. We show that XPC is protective 
against CS-induced DNA damage in mouse primary type 2 
pneumocytes, as measured by alkaline comet assay (Figure 2). 
XPC has a well-established role in GG-NER (13), however, this 
study also contributes to the growing understanding of the role 
of XPC in BER. It has been postulated that XPC aids in repair 
of oxidative DNA damage through BER, either by recognition 
of oxidative DNA lesions or through augmentation of nuclease 
activity, specifically of glycosylating proteins, hOgg1 and 
thymidine-DNA glycosylase (12–14). Urethane has been shown 
to cause DNA damage directly (etheno adducts) and indirectly 
through oxidative stress (development of oxidized bases or 
abasic intermediate sites) (30), both repaired primarily through 
BER. The increased tumor development in urethane-exposed 
XPC−/− mice and partial inhibition following the addition of 
NAC (Figures 3C and 4B) suggest that XPC-BER activity plays 
an important role in lung cancer development. However, this is 
not a direct mechanistic link and the incomplete inhibition of 
tumor development by NAC in XPC−/− mice might suggest a role 
for XPC–NER activity as well. Further supporting our finding of 
increased lung tumor development in XPC−/− mice treated with 
MCA-BHT (Figure 5). The synthetic carcinogen MCA is a PAH, 
which are repaired through the NER pathway (13). Supporting 
the importance of effective NER in protecting against lung 
cancer development are a number of studies showing a link 
between low NER activity in peripheral blood mononuclear cells 
and risk for lung cancer development (8). However, treatment 
with MCA alone leads to relatively modest numbers of lung 
tumors in mice, requiring treatment with the non-carcinogenic, 
proliferative agent BHT for aggressive lung cancer development 
(22). Considering reports of PAH induction of reactive oxygen 
species (37), this suggests an important role of XPC in both 
NER and BER for protection against lung cancer, probably with 
considerable overlap.
It is likely that other functions of XPC outside of its role in 
DNA repair are linked to lung cancer development. Decreased 
XPC expression leads to increased apoptosis and decreased 
clonogenic survival in CS-exposed bronchial epithelial cells, 
associated with accelerated emphysema development in XPC−/− 
mice (20). Similar findings of decreased clonogenic survival and 
altered cell cycle arrest were observed in XPC knockdown HeLa 
cells exposed to ultraviolet radiation in vitro (38). Interestingly, 
recent studies have suggested roles for XPC outside of its 
function in DNA damage recognition and repair. Increased 
proliferation, tumor growth and cell migration are seen in XPC 
knockdown NSCLC cells with decreased apoptosis observed 
DNA damaged skin keratinocytes deficient in XPC (39–41). It is 
likely that the impact of XPC on cell survival and proliferation 
are dependent on several factors impacting cell fate, including 
cell type, burden and type of DNA damage, and oncogene/tumor 
suppressor profiles. Further clarification of how XPC affects 
cellular function in response to CS and carcinogen exposure is 
important to further identify its role in lung cancer development. 
As the mice used in these experiments were globally deficient in 
XPC, we cannot fully rule out an effect of XPC on other processes 
including oxidative stress or local inflammation, both important 
to lung cancer development, as important in XPC CS-lung cancer 
development.
Mice treated with urethane developed few solid organ 
tumors other than lung (Table 1) with development of non-
lethal lymphomas occurring equally in XPC+/+ and −/− mice, 
consistent with age-related strain susceptibility as previously 
observed (42). This supports prior murine studies which 
have shown a specificity of XPC deficiency to lung cancer 
development (14,18). It is not known whether XPC is unique in 
its protection against CS- and carcinogen-induced lung cancer 
development, as decreased NER activity has been implicated 
in a number of malignancies, including lung cancer (8,43), 
and relatively mild number of spontaneous tumors have been 
observed in mice deficient in the BER proteins hOgg1 and 
microtT homolog 1 (44). However, deficiency of another NER 
protein, XPA, led to increases in liver tumors and oxidant-
induced mutations in the liver but no increase in lung 
tumor development (19). Further studies combining targeted 
knockdown of XPC and other DNA repair proteins with in vitro 
mechanistic studies are needed to further our understanding 
of the role of XPC and DNA repair in general in lung cancer 
development.
These studies present an intriguing role for XPC in lung 
cancer development and, along with our previous studies, 
suggest that XPC may play an important role against protecting 
against the two major smoking-related lung complications 
chronic obstructive pulmonary disease and lung cancer (20). 
Further defining the mechanisms by which XPC protects against 
CS-induced lung cancer may play an important role in prediction 
and prevention of lung cancer development in those exposed to 
CS and other carcinogens.
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